Glutaminase
Glutaminase製品
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S7655 |
CB-839CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1. |
Apoptotic sensitivity of K562 resistant (E) cells exposed to A1331852 (10 nM) for 4 h was restored following pharmacological inhibition of glutamine uptake or metabolism with GPNA (5 mM) for 48 h, CB-839 (10 μM) for 72 h, azaserine (25 μM) for 16 h and AOA (500 μM) for 24 h but not with EGCG (50 μM) for 24 h. Western blots confirmed the knockdown efficiency of the different siRNAs. ***P<0.001, **P<0.01; Error bars = Mean ± SEM (n=3).
|
|
| S7753 |
BPTESBPTES is a potent and selective Glutaminase GLS1 (KGA) inhibitor with IC50 of 0.16 μM. It has no effect on glutamate dehydrogenase activity and causes only a very slight inhibition of γ-glutamyl transpeptidase activity. |
Glu-dependent associates with sensitivity to glycolytic inhibitors 3-BrPA (left) and GLN-addicted associates with sensitivity to glutaminolytic inhibitors BPTEs.
|
|
| S8778新 |
UPGL00004 |
||
| S6417新 |
GK921 |
| 製品コード | 製品説明 | 文献中Selleckの製品使用例 | お客様のフィードバック |
|---|---|---|---|
| S7655 |
CB-839CB-839 is a potent, selective, and orally bioavailable glutaminase inhibitor with IC50 of 24 nM for recombinant human GAC. Phase 1. |
Apoptotic sensitivity of K562 resistant (E) cells exposed to A1331852 (10 nM) for 4 h was restored following pharmacological inhibition of glutamine uptake or metabolism with GPNA (5 mM) for 48 h, CB-839 (10 μM) for 72 h, azaserine (25 μM) for 16 h and AOA (500 μM) for 24 h but not with EGCG (50 μM) for 24 h. Western blots confirmed the knockdown efficiency of the different siRNAs. ***P<0.001, **P<0.01; Error bars = Mean ± SEM (n=3).
|
|
| S7753 |
BPTESBPTES is a potent and selective Glutaminase GLS1 (KGA) inhibitor with IC50 of 0.16 μM. It has no effect on glutamate dehydrogenase activity and causes only a very slight inhibition of γ-glutamyl transpeptidase activity. |
Glu-dependent associates with sensitivity to glycolytic inhibitors 3-BrPA (left) and GLN-addicted associates with sensitivity to glutaminolytic inhibitors BPTEs.
|
|
| S8778新 |
UPGL00004 |
||
| S6417新 |
GK921 |
